Skip to main content
SpringerLink
Log in

Development of a nanosomal formulation of moxifloxacin based on poly(butyl-2-cyanoacrylate)

  • Published:
Pharmaceutical Chemistry Journal Aims and scope

Abstract

A nanosomal formulation of moxifloxacin has been prepared by anionic polymerization of poly(butyl-2-cyanoacrylate) in the presence of the drug. The poly(butyl-2-cyanoacrylate) nanoparticles absorb effectively moxifloxacin with a high total content and have a considerable capacity (> 45%). The influence of reaction parameters such as pH and drug-to-polymer ratio on the nanoparticle characteristics has been studied. The efficacy of the novel formulation has been evaluated in mice infected with M. tuberculosis. It is shown that the efficacy of the proposed nanosomal formulation for i.v. administration evaluated by a decrease in the lung mycobacteria count is more than twice that of a reference preparation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. H. Pinto-Alphandary, A. Andremont, and P. Couvreur, Int. J. Antimicrob. Agents, 13, No. 3, 155–168 (2000).

    Article  PubMed  CAS  Google Scholar 

  2. R. Pandey and G. K. Khuller, Indian J. Exp. Biol., 44, No. 5, 357–366 (2006).

    PubMed  CAS  Google Scholar 

  3. R. Pandey, S. Sharma, and G. K. Khuller, Tuberculosis (Edinb.), 85, No. 5–6, 415–420 (2005).

    Article  CAS  Google Scholar 

  4. R. Rastogi, Y. Sultana, A. Ali, et al., Curr. Drug Delivery, 3, No. 1, 121–128 (2006).

    Article  CAS  Google Scholar 

  5. S. Gelperina, K. Kisich, M. D. Iseman, et al., Am. J. Respir. Crit. Care Med., 15, 172, No. 12, 1487–1490 (2005).

    Article  Google Scholar 

  6. J. Kreuter, ed., “Nanoparticles,” in: Colloidal Drug Delivery Systems, Marcel Dekker, New York (1994), pp. 291–342.

  7. C. Vautheir, C. Dubernet, E. Fattal, et al., Adv. Drug Delivery Rev., 55, No. 4, 519–548 (2003).

    Article  Google Scholar 

  8. E. Fattal, M. Youssef, P. Couvreur, et al., Antimicrob. Agents Chemother., 33, No. 9, 1540–1543 (1989).

    PubMed  CAS  Google Scholar 

  9. I. N. Skidan, S. E. Gel(perina, S. E. Severin, et al., Antibiot. Khimioter., 48, No. 1, 23–26 (2003).

    PubMed  CAS  Google Scholar 

  10. M. Youssef, E. Fattal, M.-J. Alonso, et al., Antimicrob. Agents Chemother., 32, No. 8, 1204–1207 (1988).

    PubMed  CAS  Google Scholar 

  11. E. A. Oganesyan, A. P. Bud(ko, Yu. V. Stukalov, et al., Antibiot. Khimioter., 50, No. 8–9, 15–19 (2005).

    CAS  Google Scholar 

  12. F. Fawaz, F. Bonini, J. Maugein, et al., Int. J. Pharm., 168, 225–259 (1998).

    Article  Google Scholar 

  13. M. I. Perel(man, G. B. Sokolova, G. N. Mozhokhina, et al., Antibiot. Khimioter., 49, No. 6, 20–24 (2004).

    Google Scholar 

  14. L. S. Strachunskii and V. A. Krechikov, Klin. Mikrobiol. Antimicrob. Khimioter., 3, 3–40 (2001).

    Google Scholar 

  15. S. J. Douglas, L. Illum, S. S. Davis, et al., J. Colloid Interface Sci., 101, No. 1, 149–175 (1984).

    Article  CAS  Google Scholar 

  16. F. Fawaz, M. Guyot, A. M. Lagueny, et al., Int. J. Pharm., 154, 191–203 (1997).

    Article  CAS  Google Scholar 

  17. M. Fresta, G. Puglisi, G. Giammona, et al., J. Pharm. Sci., 84, No. 7, 895–901 (1995).

    Article  PubMed  CAS  Google Scholar 

  18. C. M. Shoen, M. S. DeStefano, M. R. Sklaney, et al., Int. J. Antimicrob. Agents, 53, No. 4, 641–645 (2004).

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Research Center for Molecular Diganostics and Therapy, Moscow, Russia

    E. V. Shipulo, O. O. Maksimenko, L. V. Vanchugova, E. A. Oganesyan, P. G. Sveshnikov, E. S. Severin & S. E. Gel’perina

  2. State Scientific Center for Applied Microbiology and Biotechnology, Obolensk, Moscow Oblast, Russia

    I. I. Lyubimov & S. F. Biketov

  3. National Jewish Medical Research Center, Denver, USA

    L. B. Heifets

Authors
  1. E. V. Shipulo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. I. I. Lyubimov
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. O. O. Maksimenko
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. L. V. Vanchugova
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. E. A. Oganesyan
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. P. G. Sveshnikov
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. S. F. Biketov
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. E. S. Severin
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. L. B. Heifets
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. S. E. Gel’perina
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

__________

Translated from Khimiko-Farmatsevticheskii Zhurnal, Vol. 42, No. 3, pp. 43–47, March, 2008.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Shipulo, E.V., Lyubimov, I.I., Maksimenko, O.O. et al. Development of a nanosomal formulation of moxifloxacin based on poly(butyl-2-cyanoacrylate). Pharm Chem J 42, 145–149 (2008). https://doi.org/10.1007/s11094-008-0073-2

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11094-008-0073-2

Keywords

Search

Navigation